Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 30;11(11):3081.
doi: 10.3390/jcm11113081.

Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?

Marijana Tadic  1 , Cesare Cuspidi  2
Affiliations
Editorial

Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?

Marijana Tadic et al. J Clin Med. .

Abstract

Sacubitril/valsartan represents the combination that became "sine qua non" in the treatment of heart failure with reduced ejection fraction (HFrEF) with significant positive effect on major cardiovascular events [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014;371:993–1004. doi: 10.1056/NEJMoa1409077. - DOI - PubMed
    1. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., Falk V., González-Juanatey J.R., Harjola V.P., Jankowska E.A., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;37:2129–2200. - PubMed
    1. Solomon S., McMurray J., Anand I., Ge J., Lam C.S., Maggioni A.P., Martinez F., Packer M., Pfeffer M.A., Pieske B., et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 2019;381:1609–1620. doi: 10.1056/NEJMoa1908655. - DOI - PubMed
    1. Heidenreich P.A., Bozkurt B., Aguilar D., Allen L.A., Byun J.J., Colvin M.M., Deswal A., Drazner M.H., Dunlay S.M., Evers L.R., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2022;79:1757–1780. doi: 10.1016/j.jacc.2021.12.011. - DOI - PubMed
    1. Jackson A.M., Jhund P.S., Anand I.S., Düngen H.D., Lam C.S., Lefkowitz M.P., Linssen G., Lund L.H., Maggioni A.P., Pfeffer M.A., et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur. Heart J. 2021;42:3741–3752. doi: 10.1093/eurheartj/ehab499. - DOI - PMC - PubMed

Publication types

LinkOut - more resources